Circulating Levels of the Cardiovascular Biomarkers ST2 and Adrenomedullin Predict Outcome within a Randomized Phase III Lung Cancer Trial (RASTEN)

Circulating Levels of the Cardiovascular Biomarkers ST2 and Adrenomedullin Predict Outcome within a Randomized Phase III Lung Cancer Trial (RASTEN)

Cardiovascular comorbidity is common in small cell lung cancer (SCLC) and may significantly affect treatment tolerability and patient outcome. Still, there are no established biomarkers for objective and dynamic assessment as a tool for improved treatment decisions. We have investigated circulating...

Full description

Bibliographic Details
Main Authors: Emelie Gezelius, Pär-Ola Bendahl, Widet Gallo, Kelin Gonçalves de Oliveira, Lars Ek, Bengt Bergman, Jan Sundberg, Olle Melander, Mattias Belting
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Cancers
Subjects:
small cell lung cancer
cardiovascular biomarkers
individualized treatment
Online Access:https://www.mdpi.com/2072-6694/14/5/1307

Similar Items

Similar Items